Document is current

Article History

Received: 19 December 2025

Accepted: 10 March 2026

First Online: 17 April 2026

Disclosure

: The authors whose names are listed immediately below report affiliation or involvement with Cebiotex SL with a financial or nonfinancial interest in the subject matter or materials discussed in this manuscript: Antonio Pérez Campos, Anna Huguet Ninou, Lucas Krauel, José Antonio Tornero García, Ester Lopera de Llanos, Ann-Kathrin Gruber. C.S. has received research funding (institution) from IDRX and Blueprint; consulting fees (advisory role) from NewBay, IDRX, Cogent, and Deciphera; payment for lectures from Roche, PharmaMar, and Deciphera; and travel grants from Gilead and PharmaMar. J.M.B. has received honoraria for consulting or advisory board participation and expert testimony from PharmaMar, Bayer, GSK, Deciphera, Boehringer Ingelheim, Cogent Biosciences, Roche, Tecnofarma and Asofarma; and research funding for clinical studies (institutional) from Deciphera, PharmaMar, Eli Lilly and Company, BMS, Pfizer, Boehringer Ingelheim, Synox, ABBISKO, Biosplice, Lixte, Karyopharm, Rain Therapeutics, INHIBRX, Immunome, Philogen, Cebiotex, PTC Therapeutics, Inc. and SpringWorks therapeutics. Javier Martin-Broto is CEO of Sarcoma Research Solutions. A.S. received travel and congress assistance from Lilly, Merck, Roche, PharmaMar, Sanofi, and Cebiotex. Educational activities from Boehringer Ingelheim, PharmaMar, Boston Scientific, and Deciphera. Consultancy from Boehringer Ingelheim, GSK, PharmaMar, Deciphera and Springworks. R.A. reports having participated in a consulting/advisory board for Novartis; having consulting fees for AstraZeneca, Novartis, PharmaMar, and Roche; having received personal honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events for Boehringer and Deciphera; having personal support for attending meetings and travel from Merck Sharp & Dohme, PharmaMar, and Roche and research funding for clinical studies (institutional) from Deciphera, PharmaMar, Eli Lilly and Company, BMS, Pfizer, Boehringer Ingelheim, Rain Therapeutics, Philogen, Cebiotex, AstraZeneca, Roche, Daiichi Sankyo, Janssen Cilag and MSD.N.H. reports personal honoraria from PharmaMar (expert testimony, travel grant, and invited speaker), Tecnofarma (honoraria), and Deciphera (advisory). Institution: Research support (clinical trials or translational projects) from PharmaMar, Eli Lilly and Company, Adaptimmune Therapeutics, Lixte, Karyopharm, Deciphera, GSK, AYALA, INBRX, PTC Therapeutics, RAIN Therapeutics, Boehringer, Phyllogen, Abiskko, BMS, Pfizer, COGENT Therapeutics, and Cebiotex. Non-remunerated leadership roles for GEIS, SELNET, and CTOS and non-remunerated membership or affiliation with ESMO, SEOM, GEIS, ASCO, CTOS, and EORTC. H.C. received honoraria from Cebiotex S.L. for the pharmacokinetic analyses. All remaining authors declare no conflicts of interest related to this study.